Indication: For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
Pharmacology: Dichlorphenamide is an oral carbonic anhydrase inhibitor indicated for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow).
Mechanism Of Action: Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow), although the mechanism by which they do this is not fully understood. Evidence suggests that HCO3- ions are produced in the ciliary body by hydration of carbon dioxide under the influence of carbonic anhydrase and diffuse into the posterior chamber which contains more Na+ and HCO3- ions than does plasma and consequently is hypertonic. Water is then attracted to the posterior chamber by osmosis, resulting in a drop in pressure.
Drug Category: Antiglaucomic Agents; Ophthalmics; ATC:S01EC02
Interactions:
DrugBank: Interactions for Dichlorphenamide
Interactions for Dichlorphenamide:
Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as
anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
Chemical IUPAC Name: 4,5-dichlorobenzene-1,3-disulfonamide
